Stocks
GSK Jemperli Shows Sustained Response in Rectal Cancer Trial
GSK's Jemperli (dostarlimab) achieved a sustained complete clinical response rate at one year in a Phase 2 trial for specific rectal cancer...
GSK's Jemperli (dostarlimab) achieved a sustained complete clinical response rate at one year in a Phase 2 trial for specific rectal cancer...